Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Director Sells 3,377 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 3,377 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total transaction of $64,331.85. Following the transaction, the director now owns 17,354 shares in the company, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

SI-BONE Price Performance

Shares of NASDAQ:SIBN opened at $18.90 on Friday. The business has a 50 day moving average price of $16.10 and a 200 day moving average price of $15.52. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a market cap of $805.42 million, a price-to-earnings ratio of -20.54 and a beta of 0.82. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Research analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Truist Financial upped their price target on SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th.

Institutional Investors Weigh In On SI-BONE

Institutional investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new stake in shares of SI-BONE in the 1st quarter worth approximately $34,000. Virtus Fund Advisers LLC acquired a new position in shares of SI-BONE in the fourth quarter valued at $40,000. Mainstream Capital Management LLC bought a new position in SI-BONE in the fourth quarter worth $53,000. GAMMA Investing LLC lifted its position in SI-BONE by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock worth $55,000 after purchasing an additional 3,867 shares during the period. Finally, Virtus Advisers LLC acquired a new stake in SI-BONE during the first quarter worth $58,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.